Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Mark Hallett MD
Mark Hallett MD Editor-in-Chief
Nina Schor MD, PhD
Nina F. Schor MD, PhD Advisory Board
Argye Hillis MD, MA
Argye Elizabeth Hillis MD, MA Associate Editor
See All Experts
Published in Neurology

Journal Scan / Research · August 11, 2024

DOACs and Antiseizure Medications for Atrial Fibrillation and Epilepsy and the Risk of Thromboembolic Events

JAMA Neurology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Zafer Keser MD

JAMA Neurology
Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events
JAMA Neurol 2024 Jul 08;[EPub Ahead of Print], EK Acton, S Hennessy, MA Gelfand, CE Leonard, WB Bilker, D Shu, AW Willis, SE Kasner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated